APOL1 Counseling Training Program for Genetic Predisposition to Disease
Phase-Based Progress Estimates
Effectiveness
Safety
Genetic Predisposition to Disease+5 More
APOL1 Counseling Training Program - BehavioralEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial will test whether a chatbot can help African American living kidney donors make informed decisions about their health.
Eligible Conditions
- Genetic Predisposition to Disease
- Chronic Kidney Disease (CKD)
- Predisposition, Genetic
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 5 Secondary · Reporting Duration: Post-intervention, up to 5 years
Approximately Day 14
Genetic variation knowledge assessment index (GKAI)
Health Professionals Beliefs about Race (HPBR) scale
Practical Knowledge and Self-Efficacy in Genetic Counseling
Racial attributes in clinical evaluation (RACE) scale
Approximately Month 12
Acceptability of Intervention Measure (AIM)
Feasibility of Intervention Measure (FIM)
Intervention Appropriateness Measure (IAM)
Approximately Month 25
Barriers and Facilitators to APOL1 testing Implementation
Approximately Month 36
Clinical Sustainability Assessment Tool (CSAT)
Year 5
Number and quality of prescribed Post-Test counseling practices
Number and quality of prescribed Pre-Test counseling practices
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Counseling Training Program
1 of 1
Experimental Treatment
12 Total Participants · 1 Treatment Group
Primary Treatment: APOL1 Counseling Training Program · No Placebo Group · N/A
Counseling Training Program
Behavioral
Experimental Group · 1 Intervention: APOL1 Counseling Training Program · Intervention Types: BehavioralTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: post-intervention, up to 5 years
Who is running the clinical trial?
Northwestern UniversityLead Sponsor
1,432 Previous Clinical Trials
769,525 Total Patients Enrolled
2 Trials studying Genetic Predisposition to Disease
282 Patients Enrolled for Genetic Predisposition to Disease
Georgetown UniversityOTHER
317 Previous Clinical Trials
120,465 Total Patients Enrolled
1 Trials studying Genetic Predisposition to Disease
261 Patients Enrolled for Genetic Predisposition to Disease
Elisa J Gordon, PhD, MPHPrincipal InvestigatorNorthwestern University
1 Previous Clinical Trials
8 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:The individual is not cognitively impaired.
Adults are individuals who are 18 years old and older.
will be offered the intervention
Transplant nephrologists who are evaluating live kidney donor candidates will be offered the intervention.
The person is not vision impaired.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments